CIK 0000899923
- Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 870494517
- Phone
- +1 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $34,252
- in 1 filing
Net −$34,252. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Exercise or conversion | +4,328 | $23.11 | $100K | 445,161 |
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Sale | −4,328 | $44.00 | $190K | 440,833 |
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Exercise or conversion | +58,138 | $30.34 | $1.8M | 498,971 |
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Sale | −58,138 | $44.00 | $2.6M | 440,833 |
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Exercise or conversion | +3,862 | $30.34 | $117K | 444,695 |
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Sale | −3,862 | $44.00 | $170K | 440,833 |
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Exercise or conversion · Incentive Stock Option (right to buy) | −4,328 | 0 | ||
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Exercise or conversion · Incentive Stock Option (right to buy) | −3,862 | 0 | ||
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −70,672 | 0 | ||
| 2019-08-01 | Capone Mark Christopher President & C.E.O. | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −58,138 | 0 | ||
| 2019-03-12 | McDade Ralph L President Myriad RBM, Inc. | Sale | −1,975 | $31.00 | $61K | 122,604 |
| 2019-01-02 | Tobin Bernard President Crescendo BioScience | Returned to the company | −3,734 | $29.00 | $108K | 157,752 |
| 2018-11-29 | Phanstiel S. Louise Director | Grant or award | +9,360 | 40,103 | ||
| 2018-11-29 | DREISMANN HEINRICH Director | Grant or award | +9,360 | 43,103 | ||
| 2018-11-29 | LANGER DENNIS Director | Grant or award | +9,360 | 49,103 | ||
| 2018-11-29 | GILBERT WALTER PHD Director | Grant or award | +9,360 | 36,603 | ||
| 2018-11-29 | HENDERSON JOHN T Director | Grant or award | +9,360 | 59,103 | ||
| 2018-11-29 | BEST LAWRENCE C Director | Grant or award | +9,360 | 49,103 | ||
| 2018-10-17 | Riggsbee Richard Bryan Chief Financial Officer | Returned to the company | −3,327 | $44.45 | $148K | 146,966 |
| 2018-09-30 | Ford Alexander President, MGL | Returned to the company | −1,830 | $46.00 | $84K | 127,177 |
Page 37 of 60 · 1,194 trades